Roxadustat: More Than an Erythropoietic Agent?
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Jhee J, Oh D, Seo J, Lee C, Chung M, Park J
. Short-term Blood Pressure Variability and Incident CKD in Patients With Hypertension: Findings From the Cardiovascular and Metabolic Disease Etiology Research Center-High Risk (CMERC-HI) Study. Am J Kidney Dis. 2022; 81(4):384-393.e1.
DOI: 10.1053/j.ajkd.2022.08.017.
View
2.
Kong W, Wu X, Shen Z, Wang M, Liu X, Lin X
. The Efficacy and Safety of Roxadustat for the Treatment of Posttransplantation Anemia: A Randomized Study. Kidney Int Rep. 2024; 9(6):1705-1717.
PMC: 11184400.
DOI: 10.1016/j.ekir.2024.04.021.
View
3.
Li J, Yang M, Yu Z, Tian J, Du S, Ding H
. Kidney-secreted erythropoietin lowers lipidemia via activating JAK2-STAT5 signaling in adipose tissue. EBioMedicine. 2019; 50:317-328.
PMC: 6921330.
DOI: 10.1016/j.ebiom.2019.11.007.
View
4.
Guglielmo C, Bin S, Cantarelli C, Hartzell S, Angeletti A, Donadei C
. Erythropoietin Reduces Auto- and Alloantibodies by Inhibiting T Follicular Helper Cell Differentiation. J Am Soc Nephrol. 2021; 32(10):2542-2560.
PMC: 8722788.
DOI: 10.1681/ASN.2021010098.
View
5.
Donadei C, Angeletti A, Cantarelli C, DAgati V, La Manna G, Fiaccadori E
. Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease. JCI Insight. 2019; 5.
PMC: 6542617.
DOI: 10.1172/jci.insight.127428.
View